Classification and Diagnosis of Patients with Medically Unexplained Symptoms

Robert C. Smith, MD, ScM and Francesca C. Dwamena, MD

Department of Medicine, Division of General Medicine, Michigan State University, East Lansing, Michigan 48824, USA.

Patients with medically unexplained symptoms (MUS) have little or no demonstrable disease explanation for the symptoms, and comorbid psychiatric disorders are frequent. Although common, costly, distressed, and often receiving ill-advised testing and treatments, most MUS patients go unrecognized, which precludes effective treatment. To enhance recognition, we present an emerging perspective that envisions a unitary classification for the entire spectrum of MUS where this diagnosis comprises severity, duration, and comorbidity. We then present a specific approach for making the diagnosis at each level of severity. Although our disease-based diagnosis system dictates excluding organic disease to diagnose MUS, much exclusion can occur clinically without recourse to laboratory or consultative evaluation because the majority of patients are mild. Only the less common, “difficult” patients with moderate and severe MUS require investigation to exclude organic diseases. By explicitly diagnosing and labeling all severity levels of MUS, we propose that this diagnostic approach cannot only facilitate effective treatment but also reduce the cost and morbidity from unnecessary interventions.

KEY WORDS: somatization; medically unexplained symptoms; diagnosis and classification; primary care mental health; DSM-IV.

DOI: 10.1007/s11606-006-0067-2
© 2007 Society of General Internal Medicine 2007;22:685–691

Patients with medically unexplained symptoms (MUS), also called somatization, represent one of the most common conditions in medicine.1–3 We define MUS as those physical symptoms having little or no basis in underlying organic disease;4 when organic disease exists, the symptoms are inconsistent with or out of proportion to it.5 We caution that people with MUS are not necessarily abnormal. Many exhibit it but seldom or never seek care.6 MUS becomes a medical issue when it leads to health-care-seeking for feared but nonexistent physical illness.7,8

The prevalence of all MUS in the outpatient setting is reported from 25% to 75%, and pain is the most common type, 1–3 i.e., on average, approximately one-half or more of all outpatients have little or no physical disease explanation for their symptoms. Consistent with this, Kroenke and Mangelsdorf found, among all new symptoms, that only 16% had an organic disease basis.9

Limited evidence suggests that treatment in primary care and specialty settings is effective, but MUS patients seldom receive it.10,11 They first must be recognized and diagnosed. In addition to lack of treatment, inadequate identification occasions safety and cost problems: ill-advised lab testing and “trial treatments” can lead to iatrogenic complications and increased costs.12–16 To facilitate diagnosis, we present an emerging consensus that proposes a unitary diagnostic classification system of MUS,4,17–24 We also review the diagnostic approach it requires.

CURRENT WAYS TO CLASSIFY MUS

Psychiatric Nosology—DSM-IV

Table 1 summarizes the criteria for the 7 DSM-IV Somatoform Disorders.18 The only validated entities, somatization disorder (SD) and conversion disorder, are infrequent.18,20,25–33 The failure to validate the other DSM-IV entities stems from extensive overlap of criteria.34 An abridged SD (ASD) construct requires fewer symptoms and is more comprehensive, but it also lacks validation.36,37 Multi-Somatoform Disorder (MSD)36–38 defines MUS patients of similar severity,39 and its reliability and validity presently are under investigation.36,38,40,41

MUS Patients Without a DSM-IV Diagnosis

Consistent with others,4,26,42 Smith, Gardiner, and colleagues demonstrated in 206 distressed, high-utilizing MUS patients that less than 25% had any DSM-IV Somatoform Disorders (4.4%) or ASD (18.9%). Nonetheless, 60.2% had nonsomatiform (“psychiatric”) diagnoses, primarily anxiety and depression.23 This study’s gold standard definition of MUS came from a reliable, physician-conducted chart review.22,43 The “DSM-negative” patients were less psychologically and physically distressed than those with DSM-IV Somatoform diagnoses or ASD, but they were more distressed than the normal ones. Because researchers have relied almost entirely on DSM as the gold standard for MUS, these large numbers of distressed DSM-negative patients have been
#### PROPOSED CLASSIFICATION OF MUS

Many have favored an approach that lumps all “MUS” patients into 1 category, and other names have been suggested, e.g., “MUS Spectrum Disorder” or “Physical Symptom Disorder”.

Table 2 provides a template and supporting data for an evolving unitary or continuum model, and it identifies where the categorical disease entities fall on the spectrum of MUS.

In summarizing this classification, we also have been guided by Klinkman, Coyne, and colleagues who identified 3 parameters for classifying depression, and we have applied them to MUS: severity, duration, and comorbidity.

#### Diagnosis of MUS

MUS can be diagnosed only by excluding organic diseases.

After that, clinicians also can make DSM-IV Somatoform diagnoses or ASD—or one of the named syndromes such as IBS.

Our focus on excluding organic diseases does not preclude the possibility of underlying, explanatory psychophysiological changes, nicely summarized recently for IBS, nor does it preclude that improved understanding in the future could provide organic disease explanations for what we now call MUS.

Nevertheless, with our present universally applied, disease-based classification system, the only useful, broadly applicable way to diagnose MUS patients is to exclude organic disease. Our long-range goal, however, continues to be integrating psychosocial and biomedical aspects to produce the biopsychosocial diagnoses articulated by Engel over a quarter of a century ago.

Bespeaking our progress toward biopsychosocial medicine, the isolated-disease focus needed for diagnosis does not apply to treatment because psychosocial factors already are demonstrably key elements in successful medical treatment.

We recommend the following clinical guidelines to exclude organic diseases.

**Normal to Mild MUS.** The label “normal to mild” reflects the infrequent, appropriate seeking of reassurance for worrisome symptoms, a normal illness behavior. Symptoms may be of any type and intensity but usually are few and mild, and they seldom require much laboratory or other diagnostic investigation.

Rather, excluding organic diseases occurs primarily by history and physical examination and by follow-

---

### Table 1. DSM-IV Somatoform Disorders

| Disorder Name | Criteria |
|---------------|----------|
| Somatization disorder | Of many years duration, begins before age 30, is more common in women, and has (over a lifetime) at least four pain symptoms, two gastrointestinal symptoms, one sexual symptom, and one pseudoneurological symptom. |
| Undifferentiated somatoform disorder | Is a residual category for patients who do not meet criteria for other somatoform disorders, is of at least 6 months duration, has no gender or age limit, and has at least one symptom. |
| Conversion disorder | Usually occurs acutely and lasts about 2 weeks but may be recurring or chronic, is most frequent in women before age 35, and exhibits one or more motor, sensory, or seizure (pseudoneurological) symptoms. |
| Pain disorder | Occurs at any age, more often in women, usually is chronic and persistent, and has one or more pain symptoms that are the predominant focus of the presentation and that are not restricted to dyspareunia. |
| Hypochondriasis | Occurs at any age in males and females, may be more common in early adulthood, is at least 6 months duration and often chronic and persistent, and has one or more symptoms that provoke an unwarranted fear (which is not delusional or restricted to concerns about appearance) of organic disease even after reassurance and appropriate investigation. |
| Body dysmorphic disorder | Begins in adolescence, occurs in males and females equally, is chronic and persistent, and is suggested by preoccupation with an alleged defect in appearance that causes patients to feel ugly (anorexia nervosa is classified elsewhere); when of delusional intensity, an additional diagnosis of delusional disorder, somatic type is made. |
| Somatization disorder not otherwise specified | Includes disorders with somatoform symptoms that do not meet the above criteria, such as pseudoeyesis and symptoms of less than 6 months duration. |

---

Medical MUS Syndromes

In medical settings, chronic MUS patients typically are understood as “difficult” or as one of several named MUS conditions, e.g., Chronic Fatigue Syndrome, Irritable Bowel Syndrome, Fibromyalgia. These also lack validity because of overlapping criteria.

---

#### PROPOSED CLASSIFICATION OF MUS

Many have favored an approach that lumps all “MUS” patients into 1 category, and other names have been suggested, e.g., “MUS Spectrum Disorder” or “Physical Symptom Disorder”.

Table 2 provides a template and supporting data for an evolving unitary or continuum model, and it identifies where the categorical disease entities fall on the spectrum of MUS.

In summarizing this classification, we also have been guided by Klinkman, Coyne, and colleagues who identified 3 parameters for classifying depression, and we have applied them to MUS: severity, duration, and comorbidity.

In continuum or dimensional model, SD is at the very severe end, whereas ASD and MSD also are labeled severe. Those who do not resemble DSM-IV entities (DSM-negative; Minor Acute Illness) are in the moderate range of the spectrum, merging into mild and normal MUS patients when health care–seeking and psychological distress decrease.

Extrapolating from many of the criteria that we estimate in Table 2 that ~80% of all MUS patients in a clinical setting are “mild”–acute symptoms, low utilization, respond to reassurance and resolution of stressors, and present little difficulty for providers. Although often receiving much testing, they typically are not recognized as MUS at all; they are viewed, for example, as “noise in the system.” The remaining 20% of MUS patients are high utilizers, which vary from subacute to chronic, and exist on the severity spectrum from “moderate” to “severe.” This group features the physical disability and severe psychological problems that command most of our clinical attention, the ones providers usually think of as somatization, MUS, or the “difficult” patient.

Comorbid organic and psychiatric diseases are common across the entire severity spectrum, but psychological dysfunction and psychiatric diagnoses increase as the MUS becomes more severe, as do functional disability and joblessness, a history of physical or sexual abuse, and prescription and nonprescription substance misuse.

In primary care patients with SD, 10 psychiatric problems were more prevalent than in the general population, in the order of decreasing prevalence: depression, anxiety, phobia, panic, alcohol abuse, obsessive-compulsive, antisocial personality, schizophrenia, cognitive impairment, and mania. Some posit that personality disorders in general are comorbid conditions.

---

#### Diagnosis of MUS

MUS can be diagnosed only by excluding organic diseases. After that, clinicians also can make DSM-IV Somatoform diagnoses or ASD—or one of the named syndromes such as IBS.

Our focus on excluding organic diseases does not preclude the possibility of underlying, explanatory psychophysiological changes, nicely summarized recently for IBS, nor does it preclude that improved understanding in the future could provide organic disease explanations for what we now call MUS.

Nevertheless, with our present universally applied, disease-based classification system, the only useful, broadly applicable way to diagnose MUS patients is to exclude organic disease. Our long-range goal, however, continues to be integrating psychosocial and biomedical aspects to produce the biopsychosocial diagnoses articulated by Engel over a quarter of a century ago.

Bespeaking our progress toward biopsychosocial medicine, the isolated-disease focus needed for diagnosis does not apply to treatment because psychosocial factors already are demonstrably key elements in successful medical treatment.

We recommend the following clinical guidelines to exclude organic diseases.

**Normal to Mild MUS.** The label “normal to mild” reflects the infrequent, appropriate seeking of reassurance for worrisome symptoms, a normal illness behavior. Symptoms may be of any type and intensity but usually are few and mild, and they seldom require much laboratory or other diagnostic investigation. Rather, excluding organic diseases occurs primarily by history and physical examination and by follow-
Table 2. The Clinical Spectrum of MUS*

| Common name | Normal to mild –80% | Moderate –15% | Severe –5% | Very severe<1% |
|-------------|---------------------|---------------|------------|---------------|
| Utilization| Low[^9] | High[^23,44] | High[^3] | High[^3,91,92] |
| Age of onset | Any | Any | Any | <30 years[^18] |
| Specific physical symptoms | Any | Any | Musculoskeletal, GI, nervous, or ill-defined systems[^93,94] | Musculoskeletal, GI, nervous, or ill-defined systems[^93,94] |
| Body systems involved | Any | Any | >6 mos[^18] | “Chronic” >6 mos[^18,39] |
| Symptom duration[^25] | “Acute” days to weeks | “Subacute” < 6 mos. | >3 (men) & >5 (women) for ASD[^35,96] | >7[^18] |
| Number of symptoms† | Few | Any | Yes, but recur frequently | No, but worsen with stress |
| Symptoms occur and recur with external stress and clear when it abates[^51] | Yes | Yes | Yes | Yes |
| Depression, anxiety, dysthymia, and other psychiatric problems| ? | ? | ? | ? |
| Personality structure | “Normal” | ? | Personality disorder[^99,100] | 61–72% Personality disorder[^101,102] |
| Prevalence, community | ~100%[^6,103] | ? | 4.4–22%[^20,25–27,35,104] | 0.03–0.7%[^18,20,25–27] |
| Prevalence, all outpatients | ? | ? | 33%[^7] | 5–7%[^3,92] |
| Prevalence, inpatients | ? | ? | ? | 9%[^91] |
| Prevalence, outpatients with >5 visits per year | ? | 51% had MAI[^44] | 14% (includes very severe)[^44] | 88–99%[^61,99] |

MUS = medically unexplained symptoms; MAI = minor acute illness (derived from chart rating); DSM = Diagnostic and Statistical Manual of Mental Disorders; ASD = abridged somatization disorder; MSD = Multi-Somatoform Disorder; SD = somatization disorder; GI = gastrointestinal.

*A Comorbid medical disease is frequent throughout the spectrum; psychiatric disease also is prevalent, but increases with increasing severity and utilization in MUS.

^1Because there are many data on SD, a separate column (“Very severe”) has been included, although SD is very rare.

^2After organic disease is excluded, these areas particularly lend themselves to the quantification needed for explicit, concrete criteria for MUS subtyping, e.g., an average of 15 visits yearly over many years with 8 MUS symptoms during the last year that are chronic in a patient with severe depression = SEVERE; an average of 8 visits/year for the last 24 months for 5 MUS symptoms that occur intermittently but are becoming regularly persistent in a depressed patient = MODERATE; an average of 2 visits yearly for many years for 2 or 3 MUS symptoms that always occur in relationship to stress and abate with its resolution in a non-depressed patient = MILD. These examples highlight the proposed need for research to provide specific criteria for each sub-category of MUS, e.g., cutoff points for number of symptoms, number of visits, and the degree of depression.

^3This study did not separate severe and very severe.

^4Areas where data are unavailable and where research is particularly needed.

Making mild MUS explicit as a diagnosis can help resolve the problem of excessive laboratory testing, unnecessary treatments, and iatrogenic complications.[^12–16] When symptoms do not follow the expected acute clinical course (prompt resolution), an organic disease or moderate MUS with incipient high utilization is considered.

**Moderate MUS.** Moderate MUS also can have symptoms of any type and intensity, but this newly recognized group exhibits much greater psychological and physical distress and utilization than those with normal to mild MUS.[^23] Each episode of symptoms tends to be self-limited over a few weeks to months, but these patients exhibit high utilization during this symptomatic period and with recurrences of the same or a different episode, the subsequent episode often clearing completely as well; some, however, have chronic, low-grade symptoms—and merge into the next category. Initially, after a careful history and physical examination, observation over time suffices to exclude organic diseases. Nevertheless, with frequent recurrences or chronicity and increased utilization, diagnostic work-up to exclude organic disease usually is needed.

**Severe MUS.** In contrast to moderate MUS, severe MUS is characterized by more bothersome and persistent physical symptoms (more often of the type found in DSM-IV), still greater utilization, and more physical and psychological dysfunction. These patients require definitive laboratory or consultative investigation or both to exclude organic diseases in many instances—but only if not already performed.[^6,20,35,71] and if not resolved by the initial history and physical examination (H & P) where a diagnosis sometimes can be established without further investigation, e.g., a clinical
diagnosis of angina. The H & P, of course, also provides the guidance that specifies which lab tests to order. Because of the frequent presence of serious current or lifetime psychiatric disorder, one also makes sure that the diagnostic process itself does not frighten an already distressed patient. Making a clear, definitive diagnosis of moderate/severe MUS is essential: it leads the provider to the next-step—treatment—rather than repetition of testing and consultation in a few months for persisting symptoms.

Moderate and severe MUS patients require work-up, even with prominent psychological complaints and without classical textbook criteria for disease, because there is a high prevalence (prior probability) of underlying organic diseases. Patients with chronic low back pain, even with no objective neurological signs, usually require MRI, CT, or myelography to exclude impending neurological compromise, infection, or tumor. For example, 1 study showed clinically significant disease (beyond the common uncomplicated disc protrusion and degenerative changes) in 15%. The sensitivity and specificity of clinical findings, except for sciatica, are not sufficient to exclude significant organic diseases in chronic low back pain. Similarly, 35% of patients with chronic abdominal pain or altered bowel habits or both, the symptoms alone suggesting IBS, had underlying organic disease explanations. Investigation (e.g., colonoscopy) is indicated before one can diagnose these patients as MUS, especially those over 45 years of age.

Chronic pelvic pain is often thought to be caused by MUS because of prominent psychological symptoms and a negative physical exam. But, from 41% to 75% of these women have organic disease explanations, such as endometriosis, adhesions, and chronic pelvic inflammatory disease, and laparoscopy usually is recommended.

We note that recognizing some organic diseases may still not lead to success in difficult-to-treat conditions such as endometriosis, and that severe chronic organic diseases, especially those with pain, can lead to illness behaviors similar to those found in chronic MUS patients.

The following illustrate the pitfalls of relying on symptoms alone to make a diagnosis of moderate and severe MUS.

**Physical symptom criteria** alone (the Rome Criteria) for the diagnosis of IBS show a sensitivity of 0.85 and a specificity of only 0.71 when gastrointestinal (GI) symptoms (e.g., bloating, diarrhea) are used to distinguish IBS from organic diseases. In another study, 1 of 3 of all organic diseases and one-half of patients with active peptic ulcer were missed using clinical symptom criteria alone. Involving 11,366 patients, a review of 15 studies of upper GI symptoms usually has recommended ibuprofen. He reported 2 weeks later the symptoms had cleared, and that he was back to work.

**Table 3. Examples of MUS**

| Case 1 | the most common: mild MUS |
|--------|--------------------------|
| A 32-year-old man with controlled hypertension presented with the new onset of fatigue and distracting headaches, and he mentioned the threat of being laid off work. Physical examination was negative, and you empathized, supported, reassured, ordered no tests, and recommended ibuprofen. He reported 2 weeks later the symptoms had cleared, and that he was back to work. |

**DIAGNOSIS—MUS**

Severity—mild

Duration—acute

Comorbidity—essential hypertension

**Case 2—less common: moderate MUS**

A 44-year-old woman presented with yet another episode of low back pain without radicular symptoms. Her diabetes also was poorly controlled, and she had gained weight. The pain interfered with work, and she had been in the clinic with recurrences 7 times in the preceding 12 months. She was not enjoying her life and said that she had difficulty sleeping, but did not feel depressed. Physical exam revealed no neurologic deficits and mild paraspinal muscle spasm. You obtained an MRI of the spine that provided no explanation for the pain (small disc without neurologic compromise), and you implemented a program of treatment for her MUS and depression, advised exercise and weight control, and increased her metformin dose.

**DIAGNOSIS—MUS**

Severity—moderate

Duration—subacute

Comorbidity—depression and poorly controlled diabetes mellitus

**Case 3—least common: severe MUS**

A 50-year-old man related a long history of severe neck pain and headaches, virtually constant over the last 5 years. He wanted a “new approach” because he was “not getting better,” even though he went to 4 doctors and 2 pain clinics in the last year. His COPD was somewhat worse recently as well. He denied depression but did have anhedonia (lack of enjoyment), insomnia, difficulty concentrating, and weight gain over the preceding year. Physical exam was negative except for changes of COPD. You did not repeat the neck and brain MRI his previous doctor had obtained 3 months earlier but reviewed it with the radiologist and learned that several minor abnormalities (a few white matter changes and mild disc protrusion without neurologic compromise) were unrelated to his symptoms. You initiated treatment for his MUS and depression and advised a short trial of antibiotics for his COPD.

**DIAGNOSIS—MUS**

Severity—severe

Duration—chronic

Comorbidity—depression, COPD

**Differential Diagnosis**

Rare organic diseases (such as Wilson’s Disease), or those with vague or unusual presentations (such as multiple sclerosis, Lyme disease, and porphyria), or those that may have prominent psychological symptoms (such as some with carcinoma of the pancreas, subdural hematoma, or ulcerative colitis) may be misdiagnosed as MUS if the physician does not have an appropriate index of suspicion.

MUS also must be distinguished from 2 rare psychiatric disorders: factitious disorder (FD) and malingering. For the sole purpose of assuming the sick role (lack external incentives), patients with FD intentionally produce organic disease, the Munchausen Syndrome being an extreme example, or they feign psychological symptoms. Unlike MUS, patients with FD usually have obvious organic diseases, although the self-induction itself may not be recognized initially, e.g., bleeding secondary to surreptitious anticoagulant ingestion or fever.
caused by self-injection of feces. FD patients feigning psychiatric illness, however, are much more difficult to differentiate.

Malingering patients do not induce organic diseases, but they feign or grossly exaggerate physical or psychological symptoms for some external incentive such as financial compensation or obtaining drugs. MUS patients do not intentionally produce or feign their symptoms and usually do not have obvious external incentives.

A much more common primary care differential diagnosis occurs when a patient known to have significant organic disease develops MUS around the same symptoms and thus poses a difficult diagnostic problem, e.g., the patient with a recent myocardial infarction who now complains daily of chest pain. After investigation to ensure stability, the physician often is able to restrict further study.

Equally troublesome, how does one determine whether a known MUS patient develops an organic disease? It has been proposed that when a symptom represents a new organic disease, the patient will present in a clearly different way. If the physician carefully listens to and briefly examines the patient for objective evidence of disease, a significant organic disease seldom is overlooked.

CONCLUSIONS AND RECOMMENDATIONS

To maximize care and understanding, an emerging perspective indicates that MUS be classified according to: (1) severity, ranging from mild → moderate → severe; (2) duration, where most MUS patients will be acute (and mild), but the most difficult ones will be subacute and chronic (moderate and severe); and (3) comorbidity, psychiatric or medical or both.

History and physical examination and observation over time suffice to make the diagnosis, by excluding organic diseases, in ~80% of MUS patients. These “mild” patients have a few acute visits and little ongoing physical or psychological distress. Conversely, ~20% of patients, classified as “moderate” or “severe,” have increased utilization for subacute/chronic symptoms and are more physically and psychologically distressed. They typically require laboratory evaluation to exclude organic diseases and make a diagnosis of MUS.

MUS is largely untreated, common and costly, and attended by considerable distress and morbidity—some iatrogenic. Because improved recognition/diagnosis can ameliorate these problems, we recommend convening a group of experts to develop research-based, consensus definitions for each subtype of the MUS spectrum. Whereas the symptom and utilization parameters cannot themselves exclude organic diseases to diagnose MUS, they can be used to subclassify its 3 dimensions. The mild, moderate, and severe categories, we propose, must be more concretely defined, analogous to DSM criteria, if we are to maximize their potential for better defining treatment and prognosis at all levels of MUS. Only with explicit, agreed-upon criteria, for all their shortcomings, can the field move ahead. Finally, we suggest that the consensus group, at some point, include patients and work jointly with them to develop a nonpejorative name for MUS.

Acknowledgment: This study was supported in part by NIMH grant MH 57099. The authors have no conflicts of interest.

Potential Financial Conflicts of Interest: None disclosed.

Corresponding Author: Robert C. Smith, MD, ScM; Department of Medicine, Division of General Medicine, Michigan State University, East Lansing, Michigan 48824, USA (e-mail: robert.smith@ht.msu.edu).

REFERENCES

1. Katon W, Ries RK, Kleinman A. The prevalence of somatization in primary care. Compr Psych. 1984;25:208–15.
2. Barsky AJ. Hidden reasons why some patients visit doctors. Ann Intern Med. 1981;94:492–8.
3. Katon W, Russo J. Somatic symptoms and depression. J Fam Pract. 1989;29:65–9.
4. Lipowski JJ. Somatization: the concept and its clinical application. Am J Psychiatr. 1988;145:1358–68.
5. Smith RC. Somatization disorder: defining its role in clinical medicine. J Gen Intern Med. 1991;6:168–75.
6. Verbrugge LM, Aisicne PJJ. Exploring the iceberg—common symptoms and how people care for them. Med Care. 1987;25:539–69.
7. Kravitz RL. Measuring patients’ expectations and requests. Ann Intern Med. 2001;134:881–8.
8. de Waal MWM, Arnold IA, Spinhooven P, Eekhof JAH, van Hemert AM. The reporting of specific physical symptoms for mental distress in general practice. J Psychosom Res. 2005;59:89–95.
9. Kroenke K, Mangelsdorf AD. Common symptoms in ambulatory care: incidence, evaluation, therapy, and outcome. Am J Med. 1989;86:262–6.
10. Smith RC, Lein C, Collins C, et al. Treating patients with medically unexplained symptoms in primary care. J Gen Intern Med. 2003;18:478–89.
11. Smith RC, Lyles JS, Gardiner JC, et al. Primary care physicians treat patients with medically unexplained symptoms—A randomized controlled trial. J Gen Intern Med. 2006;21:671–7.
12. Deyo RA. Pain and public policy. N Engl J Med. 2000;342:1211–3.
13. Pink P. Surgery and medical treatment in persistent somatizing patients. J Psychosom Res. 1992;36:419–47.
14. Hoffman RM, Wheeler KJ, Deyo RA. Surgery for herniated lumbar discs: a literature synthesis. J Gen Intern Med. 1993;8:487–96.
15. Lightfoot JRW, Luft BJ, Rahn DW, et al. Empiric parenteral antibiotic treatment of patients with fibromyalgia and fatigue and a positive serologic result for Lyme disease. Ann Intern Med. 1993;119:503–9.
16. Adams K, Corrigan J, eds. Institute of Medicine: Priority Areas for National Action—Transforming Health Care Quality. Washington, DC 20001: The National Academies Press: 2003.
17. Barsky AJ, Klerman GL. Overview: hypochondriasis, bodily complaints, and somatic styles. Am J Psychiatr. 1983;140:273–83.
18. American Psychiatric A. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC: American Psychiatric Association; 1994.
19. Kirmayer LJ, Robbins JM. Introduction: concepts of somatization. In: Kirmayer LJ, Robbins JM, eds. Current Concepts of Somatization: Research and Clinical Perspectives. Washington, DC: American Psychiatric Press, Inc.; 1991:1–19.
20. Escobar JI, Gara M, Silver RC, Waitzkin G, Holman A, Compton W. Somatisation disorder in primary care. Br J Psychiatr. 1998;173:262–6.
21. Wessely S, Nimmunua C, Sharpe M. Functional somatic syndromes: one or many? Lancet. 1999;354:506–9.
22. Richardson RD, Engel JCC. Evaluation and management of medically unexplained physical symptoms. Neurologist. 2004;10:18–30.
23. Smith RC, Gardiner JC, Lyles JS, et al. Exploration of DSM-IV Criteria in primary care patients with medically unexplained symptoms. Psychosom Med. 2005;67:123–9.
24. Kroenke K. Physical symptom disorder: a simpler diagnostic category for somatization-spectrum conditions. J Psychosom Res. 2006;60:335–9.
25. Escobar JI, Burnam MA, Karna M, Forsythe A, Golding JM. Somatization in the community. Arch Gen Psychiatr. 1987;44:713–8.
26. Escobar JI, Swartz M, Rubio-Stipec M, Manu P. Medically unexplained symptoms: distribution, risk factors, and comorbidity. In: Kirmayer LJ, Robbins JM, eds. Current Concepts of Somatization: Research and Clinical Perspectives. Washington, DC: American Psychiatric Press, Inc.; 1991:63–78.
27. Escobar JI, Golding JM, Hough RL, Karmo M, Burnam AM, Wells KB. Somatization in the community: relationship to disability and use of services. Am J Public Health. 1987;77:837–40.

28. Sykes R. Somatoform disorders in DSM-IV: mental or physical disorders? J Psychosom Res. 2006;60(4):341–4.

29. Mayou R, Kirmayer LJ, Simon G, Kroenke K, Sharpe M. Somatoform Disorders: time for a new approach in DSM-V. Am J Psychiatry. 2005;162:847–55.

30. Couprie W, Wijdicks E, Roijmans GM, van Ginj J. Outcome in conversion disorder: a follow-up study. J Neurol Neurosurg Psychiatry. 1996;169:282–8.

31. Murphy MR. Classification of the somatoform disorders. In: Bass CM, ed. Somatization: Physical Symptoms and Psychological Illness. Oxford: Blackwell; 1990:10–39.

32. Escobar JI, Waitzkin H, Silver RC, Gara M, Holman A. Abridged somatization: a study in primary care. Psychosom Med. 1998;60:466–72.

33. Kroenke K, Spitzer RL, deGruy FV, et al. Multisomatoform disorder— an alternative to undifferentiated somatoform disorder for the somatizing patient in primary care. Arch Gen Psychiatry. 1997;54:352–8.

34. Spitzer RL, Kroenke K, Williams JBW. Validation and utility of a self-report version of the PRIME-MD. JAMA. 1999;282:1737–44.

35. Kroenke K, Spitzer RL, Williams JBW. The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms. Psychosom Med. 2002;64:258–66.

36. Kroenke K. Multisomatoform disorder. Arch Gen Psychiatry. 1998;55:756–7.

37. Dickinson WP, Dickinson LM, deGruy FV, et al. The somatization in primary care study: a tale of three diagnoses. Gen Hosp Psych. 2003;25:1–7.

38. Dickinson WP, Dickinson LM, deGruy FV, Main DS, Candidi LM, Rost K. A randomized clinical trial of a care recommendation letter intervention for somatization in primary care. Ann Fam Med. 2003;1:228–35.

39. Swartz M, Landerman R, George LK, Blazer DG, Escobar JI. Somatization disorder. In: Robbins LN, Regier DA, eds. Psychiatric Disorders in America—The Epidemiologic Catchment Area Study. Washington, DC: The Free Press; 1991:220–57.

40. Smith RC, Korban E, Kanj M, et al. A method for rating charts to aid primary care practitioner recognition. Psychosomatics. 1999;40:330–36.

41. Jackson JL, Passamonti M. The outcomes among patients presenting in primary care with a physical symptom at 5 years. J Gen Intern Med. 2005;20:1032–7.

42. Hahn SR, Kroenke K, Spitzer RL, et al. The difficult patient— prevalence, psychopathology, and functional impairment. J Gen Intern Med. 1996;11:1–8.

43. Klinkman MS, Schwenk TL, Coyne JC. Depression in primary care—more like asthma than appendicitis: the Michigan Depression Project. Can J Psychiatry. 1997;42:966–73.

44. Klinkman MS, Coyne JC, Gallo S, Schwenk TL. False positives, false negatives, and the validity of the diagnosis of major depression in primary care. Arch Fam Med. 1998;7:451–61.

45. Coyne JC, Thompson R, Klinkman MS, Nease JDE. Emotional disorders in primary care. J Consult Clin Psychol. 2002;70:788–90.

46. Coyne JC, Klinkman MS, Gallo SM, Schwenk TL. Short-term outcomes of detected and undetected depressed primary care patients and depressed psychiatric patients. Gen Hosp Psych. 1997;19:333–43.

47. Simon GE, vonKorff M, Piccinni M, Fullerton C, Ormel J. An international study of the relation between somatic symptoms and depression. N Engl J Med. 1999;341:1329–35.

48. Kroenke K. The interface between physical and psychological symptoms. Primary Care Companion. J Clin Psychiatry. 2003;5(suppl 7):11–8.

49. Smith GR, Jr, Monson RA, Ray DC. Patients with multiple unexplained symptoms. Arch Intern Med. 1986;146:49–72.

50. Fiddler M, Jackson J, Kapur N, Wells A, Creed F. Childhood adversity and frequent medical consultations. Gen Hosp Psych. 2004;26:367–77.

51. Resnick HS, Acierno R, Kilpatrick DG. Health impact of interpersonal violence 2: medical and mental health outcomes. Behav Med. 1997;23:65–78.

52. Katon W, Sullivan M, Walker E. Medical symptoms without identified pathology: relationship to psychiatric disorders, childhood and adult trauma, and personality traits. Ann Int Med. 2001;134:917–25.

53. Von Korff M, Deyo RA. Potent opioids for chronic musculoskeletal pain: flying blind? Pain. 2004;109:207–9.

54. Reid MC, Engles-Horton JL, Weber MAB, Kerns RD, Rogers EL, O’Connor PG. Use of opioid medications for chronic noncancer pain syndromes in primary care. J Gen Int Med. 2002;17:173–9.

55. Chabal C, Mikhla E, Jacobson L, Anthony M, Chaney E. Prescription opiate abuse in chronic pain patients: clinical criteria, incidence, and predictors. Clin J Pain. 1997;13:150–5.

56. Brown FW, Golding JM, Smith GR, Jr. Psychiatric comorbidity in primary care somatization disorder. Psychosom Med. 1990;52:445–51.

57. Barsky AJ. A comprehensive approach to the chronically somatizing patient. J Psychosom Res. 1998;45:301–6.

58. De Gucht V, Fischler B. Somatization: a critical review of conceptual and methodological issues. Psychosomatics. 2002;43:1–9.

59. Kandel E. Psychiatry, Psychoanalysis, and the New Biology of Mind. Washington, DC: American Psychiatric Publishing, Inc.; 2005.

60. Dressman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology 2006;130:1377–90.

61. Engel GL. The clinical application of the biopsychosocial model. Am J Psychiatry. 1980;137:535–44.

62. Engel GL. The need for a new medical model: a challenge for biomedicine. Science. 1977;196:129–36.

63. Greenhoot J, Sternbach R. Conjoint treatment of chronic pain. Adv Neurol. 1974;4:595–603.

64. Turk DC, Okifuji A. Psychological factors in chronic pain: evolution and revolution. J Consult Clin Psychol. 2002;70:678–90.

65. Fink P, Sorensen L, Engberg M, Holm M, Munk-Jorgensen P. Somatization in primary care—prevalence, health care utilization, and general practitioner recognition. Psychosomatics. 1998;40:530–8.

66. Frymoyer JW. Back pain and sciatica. N Engl J Med. 1988;318:291–300.

67. Smith RC. Patient-centered interviewing: an evidence-based method, 2nd edn. Philadelphia: Lippincott Williams and Wilkins; 2002.

68. Carragee E. Persistent low back pain. N Engl J Med. 2005;352:1891–98.

69. Fagel AA, Gordon SL. Synopsis: workshop on idiopathic low back pain. Spine. 1982;7:141–9.

70. Deyo RA. Rainville J, Kent DL. What can the history and physical examination tell us about low back pain? JAMA. 1992;268:760–5.

71. Smith RC, Greenbaum DS, Vancouver JB, et al. Psychosocial factors are associated with health care-seeking rather than diagnosis in irritable bowel syndrome. Gastroenterology. 1990;98:293–301.

72. Horwitz B, Fisher RS. The irritable bowel syndrome. N Engl J Med. 2001;344:1846–50.

73. Vanner SJ, Depew WT, Paterson WG, et al. Predictive value of the Rome Criteria for diagnosing the irritable bowel syndrome. Am J Gastroenterol. 1999;94:2912–7.

74. Rosenthal RH, Ling FW, Rosenthal TL, McNeeley GS. Chronic pelvic pain: psychological features and luraroscopic findings. Psychosomatics. 1984;25:833–41.

75. Kresch AJ, Seifer DB, Sachs LB, Barrese I. Laparoscopy in 100 women with chronic pelvic pain. Obstet Gynecol. 1984;64:672–4.

76. Hopkins MP, Smith DH. Chronic pelvic pain: profile of a resident teaching clinic. Am J Gynecol Health. 1989;3:25–29.

77. Jones HW, Wentz AC, Burnett LS. Baltimore: Williams and Wilkins; 1988.

78. Howard F. Chronic pelvic pain. Obstet Gynecol. 2003;101:594–611.

79. Liptoski ZJ, Lipsitt DR, Whybrow PC. Psychosomatic Medicine: Current Trends and Clinical Applications. New York: Oxford University Press; 1977.

80. Turk DC, Flor H. Pain-pain behaviors: the utility and limitations of the pain behavior construct. Pain. 1987;31:277–98.
86. Tibble JA, Sigthorsson G, Foster R, Forgacs I, Bjarnason I. Use of surrogate markers of inflammation and Rome Criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology 2002;123:450-60.

87. Bytzer P, Hansen JM, De Muckadell OBS, Malchow-Moller A. Predicting endoscopic diagnosis in the dyspeptic patient—the value of predictive score models. Scand J Gastroenterol. 1997;32:118–25.

88. Maayyedi P, Talley N, Fennerty M, Vakil N. Can the clinical history distinguish between organic and functional dyspepsia? JAMA. 2006;295:1566–76.

89. Smith GR, Jr., Monson RA, Ray DC. Psychiatric consultation in somatization disorder. N Engl J Med. 1986;314:1407–13.

90. Smith GR. Somatization Disorder in the Medical Setting. National Institute of Health Monograph. Washington D.C.: Supt. of Docs; 1989.

91. deGruy F, Crider J, Hashimi DK, Dickinson P, Mullins HC, Troncale J. Somatization disorder in a university hospital. J Fam Pract. 1987;25:579–84.

92. deGruy F, Columbia L, Dickinson P. Somatization disorder in a family practice. J Fam Pract. 1987;25:45–51.

93. Smith RC, Gardiner JC. Administrative database screening to identify somatizing patients. Med Care. 2006;44:799–802.

94. Smith RC, Gardiner JC, Armatti S, et al. Screening for high utilizers somatizing patients using a prediction rule derived from the management information system of an HMO—a preliminary study. Med Care. 2001;39:968–78.

95. Kleinman A. Social Origins of Distress and Disease—Depression, Neurasthenia, and Pain in Modern China. New Haven, CT: Yale University Press; 1986.

96. Escobar JJ, Rubio-Stipec M, Canino G, Kanno M. Somatic symptom index (SSI): a new and abridged somatization construct—prevalence and epidemiological correlates in two large community samples. J Nerv Ment Dis. 1989;177:140–6.

97. Katon W, Lin E, von Korff M, Russo J, Lipscomb P, Bush T. Somatization: a spectrum of severity. Am J Psychiatry. 1991;148:34–40.

98. Barsky AJ, Borus JF. Functional somatic syndromes. Ann Intern Med. 1999;130:910–21.

99. Liakow B, Othmer E, Penick EC, DeSousa C, Gabrielli W. Is Briquet’s syndrome a heterogeneous disorder? Am J Psychiatry. 1986;143:626–9.

100. Barsky AJ, Goodson JD, Lane RS, Cleary PD. The amplification of somatic symptoms. Psychosom Med. 1988;50:510–9.

101. Rost KM, Akins RN, Brown FW, Smith GR. The comorbidity of DSM-III-R personality disorders in somatization disorder. Gen Hosp Psychiatry. 1992;14:322–6.

102. Stern J, Murphy M, Bass C. Personality disorders in patients with somatization disorder: a controlled study. Br J Psychiatry. 1993;163:785–9.

103. Barsky AJ, Borus JF. Somatization and medicalization in the era of managed care. JAMA. 1995;274:1931–4.

104. Escobar JJ, Canino G. Unexplained physical complaints: psychopathology and epidemiological correlates. Br J Psychiatry. 1989;154:24–27.